TY  - JOUR
A1  - Stepniak, Beata
A1  - Kästner, Anne
A1  - Poggi, Giulia
A1  - Mitjans, Marina
A1  - Begemann, Martin
A1  - Hartmann, Annette
A1  - Van der Auwera, Sandra
A1  - Sananbenesi, Farahnaz
A1  - Krüger-Burg, Dilja
A1  - Matuszko, Gabriela
A1  - Brosi, Cornelia
A1  - Homuth, Georg
A1  - Völzke, Henry
A1  - Benseler, Fritz
A1  - Bagni, Claudia
A1  - Fischer, Utz
A1  - Dityatev, Alexander
A1  - Grabe, Hans-Jörgen
A1  - Rujescu, Dan
A1  - Fischer, Andre
A1  - Ehrenreich, Hannelore
T1  - Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes
JF  - EMBO Molecular Medicine
N2  - Fragile X syndrome (FXS) is mostly caused by a CGG triplet expansion in the fragile X mental retardation 1 gene (FMR1). Up to 60% of affected males fulfill criteria for autism spectrum disorder (ASD), making FXS the most frequent monogenetic cause of syndromic ASD. It is unknown, however, whether normal variants (independent of mutations) in the fragile X gene family (FMR1, FXR1, FXR2) and in FMR2 modulate autistic features. Here, we report an accumulation model of 8 SNPs in these genes, associated with autistic traits in a discovery sample of male patients with schizophrenia (N = 692) and three independent replicate samples: patients with schizophrenia (N = 626), patients with other psychiatric diagnoses (N = 111) and a general population sample (N = 2005). For first mechanistic insight, we contrasted microRNA expression in peripheral blood mononuclear cells of selected extreme group subjects with high-versus low-risk constellation regarding the accumulation model. Thereby, the brain-expressed miR-181 species emerged as potential "umbrella regulator", with several seed matches across the fragile X gene family and FMR2. To conclude, normal variation in these genes contributes to the continuum of autistic phenotypes.
KW  - permutation
KW  - miR-181
KW  - PGAS
KW  - FXR2
KW  - FXR1
KW  - FMR2
KW  - FMR1
KW  - identification
KW  - protein
KW  - fraxe mental retardation
KW  - CGG repeat
KW  - CPG Island
KW  - schizophrenia
KW  - expression
KW  - males
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136893
VL  - 7
IS  - 12
ER  - 
TY  - JOUR
A1  - Solimando, Antonio G.
A1  - Bittrich, Max
A1  - Shahini, Endrit
A1  - Albanese, Federica
A1  - Fritz, Georg
A1  - Krebs, Markus
T1  - Determinants of COVID-19 disease severity – lessons from primary and secondary immune disorders including cancer
JF  - International Journal of Molecular Sciences
N2  - At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders — including patients suffering from cancer — were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients.
KW  - COVID-19
KW  - SARS-CoV-2
KW  - disorder of immunity
KW  - cancer
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-319412
SN  - 1422-0067
VL  - 24
IS  - 10
ER  -